ClinicalTrials.gg
CompletedNCT05255822Updated Jan 18, 2023

INNA-051 Influenza Challenge Study

A Phase 2 interventional study of INNA-051 and Placebo in Influenza Prophylaxis, sponsored by ENA Respiratory Pty Ltd. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-18.

Sponsored by ENA Respiratory Pty Ltd · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 151 studies in Influenza, Human with a site in United Kingdom — 8 open to participants now, 13 under way, 4 of them phase 3. Influenza, Human · United Kingdom.

Enrollment
66th of 123
123 · median 129
Started
2022
with 6 others
Phase 2
38 of 151
2 open now
Registered
125th of 151
by date

Among the 151 studies in Influenza, Human with a site in United Kingdom, this one is the 66th largest by enrollment of the 123 interventional ones that give a count, is one of 7 that started in 2022, is one of 38 in phase 2, and was the 125th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

8 of the 151 studies in Influenza, Human with a site in United Kingdom are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Influenza, Human with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in healthy adults, administered prior to administration of an influenza challenge virus. This study will evaluate 2 active dose levels of INNA-051 and placebo.

Read the detailed description

Healthy participants will be administered 2 doses on INNA-051 intra-nasally and subsequently administered influenza virus as a challenge. Participants will be quarantined for 8 days. Study assessments will be performed during this period and they will monitored for symptoms of influenza infection.

03

Conditions studied

  • Influenza Prophylaxis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written
  • 18 to 55 years (inclusive) at time of consent
  • In good health with no history, or current evidence, of medical conditions, and no clinically significant test abnormalities that will interfere with participant safety
  • Agree to use highly effective

Exclusion criteria

Exclusion Criteria:

  • History of, or currently active, symptoms or signs suggestive of URT or lower respiratory tract (LRT) infection within 4 weeks prior to the first study visit
  • Any history or evidence of any other or currently active systemic comorbidities including psychiatric disorders (includes participants with a history of depression and/or anxiety)
  • Participants who have smoked ≥10 pack years at any time
  • A total body weight ≤50 kg or (BMI) ≤18 kg/m2 or ≥35kg/m2.
  • Pregnant or breast feeding
  • Any significant abnormality altering the anatomy of the nose or nasopharynx that may interfere with the nasal assessments or viral challenge, clinically significant history of epistaxis, or any nasal or sinus surgery within 3 months of the first study visit
  • vaccinations within the 4 weeks prior to the planned date of first dosing with IMP (10 days for SARS-CoV-2 vaccines, 6 months for influenza vaccine), or during the study
  • Receipt of blood or blood products, or loss (including blood donations) of 470 mL or more of blood during the 3 months prior to dosing or planned in 3 months post.
  • Receipt of any product within 3 months (or 5 half-lives of the investigational product used in the other study, whichever is greater) prior to first dose with IMP, or 3 IMPs within prior 12 months, or prior administration with a virus from the same virus family as the challenge virus, or prior participation in another respiratory viral challenge study in the preceding 3 months
  • Confirmed positive test for drugs of abuse or cotinine, history or presence of alcohol addiction, or excessive consumption of xanthine-containing substances
  • A (FEV1) \<80%
  • Positive -1 or HIV-2 test, or positive test for or C
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    INNA-051 arm 1

    INNA-051 intranasal spray low dose administered once on each of Days -4 and -2 prior to viral challenge

    Drug: INNA-051

  • Experimental
    INNA-051 arm 2

    NNA-051 intranasal spray high dose administered once on each of Days -4 and -2 prior to viral challenge

    Drug: INNA-051

  • Placebo comparator
    Placebo

    Placebo intranasal spray low dose administered once on each of Days -4 and -2 prior to viral challenge

    Other: Placebo

Interventions

  • Liquid for intra-nasal administration

  • OtherPlacebo

    Liquid for intra-nasal administration

06

What researchers measure

Primary outcomes

  1. Evaluate the antiviral effect of INNA-051 compared to placebo against influenza virus

    Change in total viral load area under the curve (AUC) measured by quantitative reverse transcriptase-polymerase chain reaction (qRT PCR) in treated participants vs. placebo participants.

    Time frame: To Day 8

Secondary outcomes

  1. Incidence of treatment emergent adverse events

    Treatment emergent adverse events in INNA-051 arms compared to placebo

    Time frame: To Day 8

  2. To evaluate the antiviral effect of INNA-051 in reducing viral load when compared to placebo

    * measurement of influenza viral load and duration of quantifiable measurements in nasopharyngeal swabs by qRT-PCR * Duration of quantifiable qRT-PCR measurements

    Time frame: To Day 8

  3. To evaluate the antiviral effect of INNA-051 in reducing detectable virus levels when compared to placebo

    - Duration of quantifiable qRT-PCR measurements

    Time frame: To Day 8

  4. To evaluate the antiviral effect of INNA-051 in reducing incidence of infection when compared to placebo

    Incidence of 2 quantifiable qRT PCR samples on 2 consecutive days

    Time frame: To Day 8

  5. To evaluate the antiviral effect of INNA-051 in reducing symptoms of influenza infection when compared to placebo

    All symptoms will be self-reported by participants on a symptom diary card

    Time frame: To Day 8

07

Study locations

1 site
  • hVIVO
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Aug 2022, 5 months.

Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 5 months is below that.

Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2022
First posted
Feb 25, 2022
StartActual
Feb 28, 2022
Primary completionActual
Aug 23, 2022
CompletionActual
Aug 23, 2022
Last update
Jan 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05255822
Lead sponsor
ENA Respiratory Pty Ltd
Responsible party
Sponsor
First posted
Feb 25, 2022
Start date
Feb 28, 2022
Primary completion
Aug 23, 2022
Completion
Aug 23, 2022
Last update
Jan 18, 2023

Study contacts

Victoria Parker, MD
principal investigator · Hvivo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: INNA-051

Start the discussion